Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B P Morgan

Showing results (101-110 of 247) with videos related to

Pageof 25
Sort By:
Immunology|February 26, 2000
Production and functional characterization of a soluble recombinant form of mouse CD59N K Rushmere, C W Van Den Berg, B P Morgan
Journal of Immunology (Baltimore, Md. : 1950)|December 10, 1999
Development of adenovirus vectors encoding rat complement regulators for use in therapy in rodent models of inflammatory diseasesY McGrath, G W Wilkinson, O B Spiller, et al.
Immunology|May 1, 1995
Regulation of CD59 expression on K562 cells: effects of phorbol myristate acetate, cross-linking antibody and non-lethal complement attackK J Marchbank, B P Morgan, C W van den Berg
Immunology|April 1, 1994
Presence of a dysfunctional form of CD59 on a CD59+ subclone of the U937 cell lineC W van den Berg, O M Williams, B P Morgan
European Journal of Immunology|July 1, 1996
Altered expression of host-encoded complement regulators on human cytomegalovirus-infected cellsO B Spiller, B P Morgan, F Tufaro, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 29, 1998
Molecular cloning and functional characterization of the pig analogue of CD59: relevance to xenotransplantationS J Hinchliffe, N K Rushmere, S M Hanna, et al.
Clinical and Experimental Immunology|February 1, 1997
Tumour cell killing using chemically engineered antibody constructs specific for tumour cells and the complement inhibitor CD59C L Harris, K S Kan, G T Stevenson, et al.
Annals of the Rheumatic Diseases|May 1, 1996
Signalling through neutrophil Fc gamma RIII, Fc gamma RII, and CD59 is not impaired in active rheumatoid arthritisJ Jones, I Laffafian, T Lawson, et al.
The Journal of Experimental Medicine|February 3, 1997
Mutational analysis of the active site and antibody epitopes of the complement-inhibitory glycoprotein, CD59D L Bodian, S J Davis, B P Morgan, et al.
Clinical and Experimental Immunology|August 8, 2002
Coupling complement regulators to immunoglobulin domains generates effective anti-complement reagents with extended half-life in vivoC L Harris, A S Williams, S M Linton, et al.
Pageof 25

Showing results (101-110 of 247) with videos related to

Sort By:
Pageof 25
Immunology|February 26, 2000
Production and functional characterization of a soluble recombinant form of mouse CD59N K Rushmere, C W Van Den Berg, B P Morgan
Journal of Immunology (Baltimore, Md. : 1950)|December 10, 1999
Development of adenovirus vectors encoding rat complement regulators for use in therapy in rodent models of inflammatory diseasesY McGrath, G W Wilkinson, O B Spiller, et al.
Immunology|May 1, 1995
Regulation of CD59 expression on K562 cells: effects of phorbol myristate acetate, cross-linking antibody and non-lethal complement attackK J Marchbank, B P Morgan, C W van den Berg
Immunology|April 1, 1994
Presence of a dysfunctional form of CD59 on a CD59+ subclone of the U937 cell lineC W van den Berg, O M Williams, B P Morgan
European Journal of Immunology|July 1, 1996
Altered expression of host-encoded complement regulators on human cytomegalovirus-infected cellsO B Spiller, B P Morgan, F Tufaro, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 29, 1998
Molecular cloning and functional characterization of the pig analogue of CD59: relevance to xenotransplantationS J Hinchliffe, N K Rushmere, S M Hanna, et al.
Clinical and Experimental Immunology|February 1, 1997
Tumour cell killing using chemically engineered antibody constructs specific for tumour cells and the complement inhibitor CD59C L Harris, K S Kan, G T Stevenson, et al.
Annals of the Rheumatic Diseases|May 1, 1996
Signalling through neutrophil Fc gamma RIII, Fc gamma RII, and CD59 is not impaired in active rheumatoid arthritisJ Jones, I Laffafian, T Lawson, et al.
The Journal of Experimental Medicine|February 3, 1997
Mutational analysis of the active site and antibody epitopes of the complement-inhibitory glycoprotein, CD59D L Bodian, S J Davis, B P Morgan, et al.
Clinical and Experimental Immunology|August 8, 2002
Coupling complement regulators to immunoglobulin domains generates effective anti-complement reagents with extended half-life in vivoC L Harris, A S Williams, S M Linton, et al.
Pageof 25